HALO
T3Halozyme Therapeutics, Inc.
OverviewHalozyme Therapeutics, Inc. is a biopharma technology platform company specializing in subcutaneous drug delivery. Its ENHANZE technology, along with Hypercon,
Halozyme Therapeutics, Inc. is a biopharma technology platform company specializing in subcutaneous drug delivery. Its ENHANZE technology, along with Hypercon, Surf Bio, and auto-injectors, enables easier administration of injectable biologics. The company generates significant royalty revenue, primarily from ENHANZE-enabled products like DARZALEX SC, PHESGO, and VYVGART Hytrulo, through partnerships with major pharmaceutical companies such as Johnson & Johnson, Roche, and argenx.
- What They Do (Plain English & Analogies)
- Halozyme Therapeutics is like a specialized delivery service for medicines. Instead of delivering packages to your door, they deliver drugs inside your body in a much more convenient way. Many important medicines, especially those for serious diseases like cancer, usually need to be given through a long IV drip in a hospital. Halozyme's core technology, ENHANZE, uses a special enzyme to temporarily open up spaces under the skin, allowing large volumes of medicine to be injected quickly and easily, often in a small shot at home or in a doctor's office. This makes treatment much easier for patients and healthcare providers, reducing administration time and improving flexibility. They also have newer technologies, Hypercon and Surf Bio, which further concentrate medicines into even smaller volumes, making them suitable for tiny auto-injectors, similar to an EpiPen, for at-home use. Their goal is to be a "one-stop shop" for biopharmaceutical companies needing advanced solutions for subcutaneous drug delivery.
- Very Brief History
- Halozyme Therapeutics, Inc. was founded in 1998. The company initially focused on its proprietary recombinant human hyaluronidase enzyme (rHuPH20), which led to the development of its flagship ENHANZE drug delivery technology. Over the years, Halozyme has built a strong portfolio through strategic partnerships with major pharmaceutical companies. In 2025, the company significantly expanded its drug delivery capabilities by acquiring Elektrofi's Hypercon technology and Surf Bio's hyperconcentration technology, both with long-duration intellectual property.
- "Street Stereotype"
- Halozyme is generally perceived by investors and analysts as a "biopharma technology platform company" or a "royalty play." The market primarily focuses on its high-margin, durable royalty streams generated from its ENHANZE technology, which is licensed to major pharmaceutical companies. There is also increasing attention on the potential of its newer drug delivery platforms, Hypercon and Surf Bio, to extend these royalty streams and diversify its revenue base.
- Subsidiaries On Linked In*
- None. Halozyme Therapeutics, Inc. operates as the primary entity, and no distinct subsidiary brands are prominently displayed on LinkedIn as separate companies.
- Customer Sectors & Example Clients
- Customer Sectors: Pharmaceuticals, Biotechnology, Oncology, Immunology, Neurology, Inflammatory Bowel Disease, Obesity. Example Clients (Partners): Johnson & Johnson (for DARZALEX SC, RYBREVANT SC), Roche (for PHESGO, OCREVUS ZUNOVO, TECENTRIQ SC), argenx (for VYVGART Hytrulo), Bristol-Myers Squibb (BMS) (for OPDIVO Qvantig), Viatris (for small volume auto-injector), Pfizer, Eli Lilly, Takeda, Chugai Pharmaceutical, Acumen Pharmaceuticals.
- New Customers / Segments They'Re Targeting
- Halozyme is actively targeting new customer segments and markets by: expanding the application of its ENHANZE technology to new drug modalities, specifically antibody drug conjugates (ADCs) and nucleic acids, which represent a significant new growth opportunity; broadening its therapeutic reach beyond oncology into areas like obesity and inflammatory bowel disease with new ENHANZE collaborations; advancing its Hypercon and Surf Bio technologies to attract partners seeking ultra-high concentration, small-volume subcutaneous delivery solutions, potentially for existing blockbuster mechanisms of action; and pursuing strategic mergers and acquisitions to acquire additional drug delivery technologies and assets with strong revenue and margin opportunities.
- How Key Themes May Help/Hurt
- The prompt asks about "motion-control build-out," which is not directly relevant to Halozyme's business model. Instead, considering the provided investment themes: * **GLP-1 Long '24: GLP1 Equip/Distrib (Help):** Halozyme's expansion into obesity and its auto-injector and hyperconcentration technologies (Hypercon, Surf Bio) could significantly benefit from the rising demand for GLP-1 drugs. These technologies could enable smaller, more convenient, at-home subcutaneous administration of GLP-1 agonists, aligning with the need for efficient distribution and equipment for these drugs. * **Biotech '24: Pharma/Therapeutics (Help):** This theme is bullish for Halozyme. As a biopharma technology platform company, Halozyme directly benefits from innovation in therapeutic solutions and strategic partnerships. Its robust R&D pipeline (ENHANZE expansion, Hypercon, Surf Bio) and successful collaborations with major pharma companies position it well to capitalize on breakthroughs in drug development, particularly in oncology and other disease areas. * **MedTech Long '25: Adv Bio Therapeutics & Regenerative Med (Help):** Halozyme's advanced drug delivery technologies (ENHANZE, Hypercon, Surf Bio) are at the forefront of bioanalytical tools and precision therapies. The growing interest in non-traditional and precision modalities, coupled with a recovery in biotech funding, supports demand for Halozyme's platforms, which enhance the delivery and patient experience of advanced biologics.
3 Main Long-Term Bull Details
- Durable and Expanding ENHANZE Royalty Streams: Halozyme benefits from 10 global blockbuster ENHANZE-enabled products, with strong growth projected for key assets like DARZALEX SC, PHESGO, and VYVGART Hytrulo. The continuous addition of new ENHANZE targets and expansion into new modalities like antibody drug conjugates (ADCs) and nucleic acids ensures long-term royalty durability and growth well into the 2040s.
- Emergence of New Growth Engines (Hypercon & Surf Bio): The acquisitions of Elektrofi's Hypercon and Surf Bio's hyperconcentration technologies provide new, long-duration intellectual property (into the mid-2040s) and are projected to generate approximately $1 billion in Hypercon royalty revenue within five years of their first launches in the mid-2030s. These technologies broaden Halozyme's capabilities and expand collaboration opportunities.
- Strategic M&A and Strong Cash Flow: Halozyme's asset-light model generates significant cash flow, which it plans to deploy towards strategic mergers and acquisitions to further strengthen its drug delivery portfolio and acquire assets with strong revenue and margin opportunities, driving both near-term and long-term growth.
3 Main Long-Term Bear Details
- Patent Expirations and Royalty Erosion: While new patents extend some protection, core ENHANZE patents are facing expirations (e.g., a key EU patent for ENHANZE rHuPH20 expires in March 2029, and a core U.S. composition of matter patent for ENHANZE expires in 2027), which could lead to a reduction in royalty rates or the emergence of generic/biosimilar competitors, impacting revenue streams.
- Reliance on Partner Success and Concentration Risk: Halozyme's revenue is heavily dependent on the commercial success and continued development of its partners' ENHANZE-enabled products. Any clinical trial failures, regulatory setbacks, or underperformance of these products, particularly those from major partners like Johnson & Johnson or Roche, could significantly impact Halozyme's royalty income.
- Competition and Litigation Risks: The drug delivery market is competitive, with other companies developing alternative subcutaneous delivery systems. Halozyme also faces ongoing litigation (e.g., with Merck regarding ENHANZE infringement and with Alteogen), which could result in significant financial losses or impact its intellectual property position.
- Competitors And Differentiation
- Competitors include other companies developing drug delivery technologies, particularly for subcutaneous administration. Specific companies mentioned or implied include Regeneron Pharmaceuticals (with its own subcutaneous delivery systems), AstraZeneca (with advanced drug delivery technologies), Moderna (developing alternative drug delivery platforms), Pfizer (developing alternative drug delivery platforms), and emerging subcutaneous drug delivery startups. Halozyme differentiates itself by aiming to be the "one-stop shop for the biopharma industry for subcutaneous drug delivery". Its competitive advantages include a comprehensive proprietary technology portfolio (ENHANZE, Hypercon, Surf Bio, and auto-injectors) offering diverse solutions for drug volumes and concentrations. The company boasts a proven track record with ENHANZE enabling 10 global blockbuster opportunities and a strong regulatory history. Furthermore, Halozyme possesses an extensive patent estate, including recent EU patents for ENHANZE extending to 2029, which provides strong defense and market exclusivity. Strategic partnerships with leading pharmaceutical companies also validate its technology and generate diverse, high-margin royalty revenue streams.
- Recent Performance & What The Market'S Focused On
- Halozyme reported a strong 2025, with total revenue growing 38% to a record $1.4 billion, and royalty revenue increasing 52% to $868 million. Key drivers were DARZALEX SC, PHESGO, and VYVGART Hytrulo. The company provided robust 2026 financial guidance, projecting total revenue of $1.71 billion to $1.81 billion (22% to 30% year-over-year growth) and royalty revenue of $1.13 billion to $1.17 billion (30% to 35% year-over-year growth). The market is primarily focused on the continued strong adoption and conversion rates of existing ENHANZE-enabled blockbuster products, the successful integration and advancement of the newly acquired Hypercon and Surf Bio technologies, and the expansion of ENHANZE into new modalities like antibody drug conjugates and nucleic acids. Investors are also closely monitoring the progress of new licensing agreements, the advancement of pipeline products into clinical trials, and the outcomes of ongoing patent litigation.
- Brands And Revenue Segments
- Brands: ENHANZE, Hylenex recombinant, Hypercon, Surf Bio, Auto-injectors. Revenue Segments: * **Royalty Revenue:** The principal growth driver, generated from the sales of partner products utilizing Halozyme's ENHANZE technology. In 2025, royalty revenue was $867.8 million. * **Product Sales:** Primarily from the sale of API (Active Pharmaceutical Ingredient) for its technologies and devices like auto-injectors. * **Collaboration and Other Revenue:** Includes upfront payments, milestone payments, and other fees from licensing agreements and partnerships.
Bull / Bear DetailsHalozyme Therapeutics maintains a strong bullish outlook as a leading biopharma technology platform company. Its ENHANZE technology continues to drive robust ro
Thesis
Halozyme Therapeutics maintains a strong bullish outlook as a leading biopharma technology platform company. Its ENHANZE technology continues to drive robust royalty revenue from blockbuster products, while strategic acquisitions of Hypercon and Surf Bio expand its subcutaneous drug delivery portfolio into new modalities like ADCs and nucleic acids. This positions Halozyme as a "one-stop shop" for partners, ensuring durable, high-margin royalty streams and significant pipeline expansion into the 2040s. (Updated: 2026-03-03)
Bull case
The continued exceptional performance and market penetration of ENHANZE-enabled blockbuster products like DARZALEX SC, PHESGO, and VYVGART Hytrulo are driving substantial royalty revenue growth. These products are expanding indications and achieving high conversion rates, with DARZALEX projected to exceed $18 billion in sales by 2028, securing Halozyme's near-term financial strength.
Halozyme has significantly broadened its drug delivery capabilities through the acquisitions of Hypercon and Surf Bio technologies, extending IP into the mid-2040s. These platforms, alongside ENHANZE and auto-injectors, position the company as a "one-stop shop" for biopharma, unlocking new collaboration opportunities and projected to generate approximately $1 billion in Hypercon royalties by the mid-2030s.
An expanding ENHANZE pipeline, with 6 new programs entering Phase I in 2026, and the emerging potential of ENHANZE with antibody drug conjugates (ADCs) and nucleic acids, represent significant long-term growth drivers. Preclinical data supports improved benefit-risk profiles for ADCs, attracting strong partner interest and accelerating royalty contributions from 2029.
Bear case
A significant portion of Halozyme's revenue is concentrated in a few key ENHANZE-enabled products and partnerships, particularly with Johnson & Johnson for DARZALEX. While an extension is expected, the expiry of the J&J agreement in 2032 poses a long-term risk. Additionally, ongoing intellectual property litigation, such as the case against Merck, introduces uncertainty and potential legal costs.
The successful integration and commercialization of newly acquired technologies like Hypercon and Surf Bio, along with the auto-injector platform, carry inherent risks. While promising, these technologies are earlier stage, with first Hypercon approvals projected for 2030-2031, meaning significant revenue contributions are still years away and subject to clinical and regulatory success.
Halozyme anticipates a sequential decrease in royalty and total revenue in Q1 2026 due to annual contractual rate resets and milestone weighting in the second half of the year. Furthermore, significant investments in new technologies like Hypercon and Surf Bio, reflected in acquired IPR&D expenses, can impact short-term profitability and diluted EPS, as seen in 2025.
Bull / Bear Case
- Bear Case
- A significant portion of Halozyme's current revenue is concentrated in a few key ENHANZE-enabled products and partnerships, notably with Johnson & Johnson for DARZALEX, whose agreement expires in 2032, posing a long-term risk. The successful integration and commercialization of newly acquired technologies like Hypercon and Surf Bio, along with the auto-injector platform, carry inherent risks as these are earlier-stage, with significant revenue contributions projected years away (Hypercon approvals in 2030-2031). Ongoing intellectual property litigation, such as the case against Merck, introduces uncertainty and potential legal costs that could impact profitability and market exclusivity. Furthermore, the company anticipates a sequential decrease in royalty and total revenue in Q1 2026 due to contractual rate resets and milestone weighting, and significant acquired IPR&D expenses have impacted short-term profitability and diluted EPS, as seen in 2025.
- Bull Case
- Halozyme Therapeutics is positioned for durable, high-margin royalty revenue and exceptional value creation well into the 2040s. This is driven by the continued strong performance and market penetration of its ENHANZE-enabled blockbuster products like DARZALEX SC, PHESGO, and VYVGART Hytrulo, with DARZALEX projected to exceed $18 billion in sales by 2028. The company has significantly expanded its drug delivery capabilities through the acquisitions of Hypercon and Surf Bio technologies, extending its intellectual property and positioning itself as a 'one-stop shop' for biopharma. An expanding ENHANZE pipeline, with 6 new programs entering Phase I in 2026, and the emerging potential of ENHANZE with antibody drug conjugates (ADCs) and nucleic acids, represent significant long-term growth drivers, with Hypercon alone projected to generate approximately $1 billion in royalties by the mid-2030s. The company reiterated strong 2026 financial guidance, including substantial royalty and EPS growth.
- More Compelling & Why
- Bull. Halozyme's forward EV/EBITDA of 9.4x is significantly below the broader Healthcare sector median of 16.64x, despite management guiding to nearly 100% EPS growth in 2026. The market appears to be under-appreciating the company's strong near-term earnings inflection and the long-term durability of its expanded drug delivery platforms. Failure to meet 2026 financial guidance, particularly royalty revenue and EPS growth targets, or a material adverse outcome in the ongoing intellectual property litigation, would flip my view.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Reported Conversion Rates and Sales Performance of DARZALEX SC, PHESGO, and OPDIVO Qvantig | Strong conversion from IV to subcutaneous formulations and robust sales growth for these blockbuster products directly drive Halozyme's royalty revenue, which is its principal growth driver. | PHESGO: Roche's reported global conversion rate from IV Perjeta (target 60%). OPDIVO Qvantig: BMS's reported conversion rate (target 30-40% by 2028). DARZALEX SC: Johnson & Johnson's reported operational sales growth (projected to exceed $18 billion in 2028). | Bullish: PHESGO global conversion rate exceeding 60%; OPDIVO Qvantig conversion rate showing strong sequential progress towards 30-40%; DARZALEX operational sales growth exceeding 2025's 22%. Bearish: Stagnation or decline in conversion rates for PHESGO or OPDIVO Qvantig; significant slowdown in DARZALEX operational sales growth. | Quarterly earnings calls and press releases from partner companies (Johnson & Johnson, Roche, Bristol-Myers Squibb), and Halozyme's quarterly earnings calls. | Partner company investor relations websites for earnings transcripts and presentations. | IQVIA: Prescription data and market share for specific ENHANZE-enabled drugs. |
| Progress in ENHANZE Application to Antibody Drug Conjugates (ADCs) | This represents a significant new market opportunity, potentially expanding ENHANZE's utility beyond monoclonal antibodies and unlocking high-value collaborations and substantial future royalty streams. | Public announcement of a new ENHANZE collaboration specifically for an ADC; initiation of a Phase I clinical study for an ENHANZE-enabled ADC. | Bullish: Signing of the first ENHANZE collaboration agreement for an ADC; public announcement of an ADC entering clinical development with ENHANZE. Bearish: No announced progress or partnerships related to ADCs with ENHANZE by year-end 2026. | Halozyme's press releases, quarterly earnings calls, and scientific conference presentations by Halozyme or potential partners. | Industry news outlets focused on oncology and ADCs (e.g., ADC Review, Cancer Research Institute news). | BioCentury: Partnership tracking for emerging drug modalities; EvaluatePharma: Pipeline analysis for ADCs in development. |
| Initiation of Phase I Clinical Studies for New ENHANZE and Hypercon Programs | Entry into Phase I signifies critical pipeline progression, laying the groundwork for future commercial products and accelerating royalty contributions from the development portfolio starting in 2029. | Number of new ENHANZE programs entering Phase I (guidance: 6 in 2026); number of new Hypercon programs entering Phase I (guidance: 2 in 2026). | Bullish: More than 6 ENHANZE programs or more than 2 Hypercon programs entering Phase I in 2026. Bearish: Fewer than 6 ENHANZE programs or fewer than 2 Hypercon programs entering Phase I in 2026. | Halozyme's quarterly earnings calls, company press releases, and clinicaltrials.gov for new study registrations. | Clinicaltrials.gov: Search for "Halozyme" or "rHuPH20" and "Phase 1" or "Hypercon" and "Phase 1" for new study registrations. | Citeline (TrialTrove): Clinical trial database for new Phase I study initiations and updates. |
| Announcement of New ENHANZE, Hypercon, or Surf Bio Collaboration and Licensing Agreements | These agreements validate Halozyme's drug delivery platforms and are crucial for expanding its future royalty revenue streams and market reach across various therapeutic areas. | Number of new ENHANZE collaborations (guidance: 1 to 3 in 2026); number of new Hypercon collaborations (guidance: 1 to 2 in 2026). | Bullish: Announcing 3 or more new ENHANZE agreements, or 2 or more new Hypercon agreements, or any new Surf Bio agreement in 2026. Bearish: Announcing fewer than 1 new ENHANZE agreement or 1 new Hypercon agreement by year-end 2026. | Halozyme's official press releases, SEC filings (Form 8-K for material agreements), and quarterly earnings call transcripts. | Biotechnology industry news websites (e.g., Fierce Biotech, Endpoints News) for partnership announcements. | EvaluatePharma: Licensing deal database for new biopharma collaborations. |
| Achievement of De-leveraging Target and Strategic M&A Announcements | Achieving the de-leveraging target demonstrates financial discipline and strengthens the balance sheet, while strategic M&A can expand the technology portfolio and drive near-term and long-term revenue growth. | Halozyme's reported net debt to EBITDA ratio (target below 1x by end of 2026); announcement of any new acquisitions (drug delivery technologies or revenue/margin assets). | Bullish: Reporting a net debt to EBITDA ratio below 1x by Q4 2026; announcement of an acquisition that significantly enhances the portfolio or adds substantial revenue. Bearish: Indications that the net debt to EBITDA target will not be met; no significant strategic acquisitions announced in 2026. | Halozyme's quarterly earnings reports and calls (for financial updates and M&A strategy), company press releases, SEC filings (Form 8-K for acquisitions). | Financial news outlets (e.g., Bloomberg, Reuters, Wall Street Journal) for M&A rumors or announcements. | S&P Capital IQ: Company financial statements and debt metrics; Mergermarket: M&A deal intelligence. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| Adjusted EBITDA | Adjusted EBITDA provides a clear view of Halozyme's operational profitability, excluding non-cash and non-recurring items, which is crucial for assessing its financial strength and ability to fund future growth. The significant decline in Q4 2025 warrants close attention. | -88.81% |
| Royalty Revenue | Royalty revenue is the principal growth driver for Halozyme, reflecting the successful adoption and conversion of ENHANZE-enabled products. Its durability into the 2040s is key to long-term value. | 51% |
| Total Revenue | Total revenue indicates the overall financial health and growth trajectory of Halozyme, driven by its ENHANZE technology and new acquisitions. Investors monitor this for sustained expansion and market penetration. | 52% |
Key QuestionsWill Halozyme meet its Q1 2026 revenue guidance, particularly the projected sequential decrease in royalty and total revenue, and reaffirm its full-year 2026 fi
Will Halozyme meet its Q1 2026 revenue guidance, particularly the projected sequential decrease in royalty and total revenue, and reaffirm its full-year 2026 financial outlook?
- Question 2
How much progress will Halozyme demonstrate in securing new ENHANZE and Hypercon licensing agreements and advancing new programs into Phase I clinical studies, especially regarding the emerging ADC opportunity?
- Question 3
Will there be any significant developments or clarity regarding the ongoing intellectual property litigation against Merck and Alteogen, particularly the scheduling and initial proceedings of the District Court case?
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Expanding drug delivery technology portfolio**: Management highlighted the acquisition of Elektrofi's Hypercon technology and Surf Bio's hyperconcentration technology, expanding their subcutaneous drug delivery capabilities from 2 to 4 technologies with long-duration IP into the mid-2040s. This aims to position Halozyme as a comprehensive solution provider for the biopharma industry. 2. **Driving long-term durable and profitable royalty revenue**: This focus is evident through the continued strong performance of existing ENHANZE-enabled blockbuster products (DARZALEX SC, PHESGO, VYVGART Hytrulo), the early growth of recently launched ENHANZE products (OCREVUS, OPDIVO, RYBREVANT, TECENTRIQ), and the expansion of the ENHANZE pipeline with projected new programs and licensing agreements. They also anticipate approximately $1 billion in Hypercon royalty revenue within five years of its first launches in the mid-2030s. 3. **Strategic M&A and disciplined capital allocation**: Management emphasized deploying strong cash flow towards strategic acquisitions that further strengthen their drug delivery portfolio and add assets with strong revenue and margin opportunities. They also plan to maintain financial discipline, expecting to de-lever to below 1x net debt to EBITDA by the end of 2026. | The call conveyed a highly positive, confident, and energized tone. The overarching takeaway was Halozyme's strong financial and operational performance in 2025, marked by record revenue and robust royalty growth, primarily driven by its ENHANZE technology. Management highlighted significant strategic expansion through the acquisition of Hypercon and Surf Bio technologies, solidifying Halozyme's position as a leading provider of subcutaneous drug delivery solutions with a clear long-term growth strategy extending into the 2040s. The emerging opportunity to apply ENHANZE to antibody-drug conjugates (ADCs) and nucleic acids was presented as an exciting new growth driver. The company also reiterated strong financial guidance for 2026, underscoring its confidence in future growth and value creation. | In the third quarter of 2025, Halozyme reported total revenue growth of 22% year-over-year to $354.3 million. Royalty revenue in Q3 2025 increased 52% year-over-year to $236 million. Product sales in Q3 2025 increased 8.7% year-over-year to $94.2 million. Revenues under collaborative agreements decreased 50.4% year-over-year to $24 million in Q3 2025. Specific year-over-year growth rates for DARZALEX subcutaneous, PHESGO, and VYVGART Hytrulo royalty revenues for Q3 2025 were not explicitly detailed in the search results. | 1. **Mechanics and future of DARZALEX collaboration with J&J**: An analyst inquired about the potential to expand the deal with J&J on DARZALEX (ENHANZE or Hypercon) and the mechanics after the ENHANZE collaboration expiry in 2032. *Management Response*: Helen Torley stated that they expect to enter discussions with Johnson & Johnson closer to 2032 to extend their ENHANZE agreement and API supply, emphasizing J&J's likely desire to continue working with Halozyme due to reliability and safety track record. Her comments specifically referred to ENHANZE. 2. **ADC strategy: Regulatory pathway and treatment paradigms**: An analyst asked about the regulatory path for improving approved ADCs with ENHANZE versus new molecules, and whether subcutaneous ADCs would truly free up infusion center time or still require IV center visits. *Management Response*: Chris Wahl explained that for converting approved ADCs from IV to SC, the regulatory path would likely involve PK non-inferiority studies, similar to monoclonal antibodies. For new products seeking additional efficacy and safety benefits, full phase trials would be required. He noted that while ADCs in combination therapy can reduce infusion center time, the increasing use of ADCs in first-line therapy and in combination with other subcutaneous drugs (many enabled by ENHANZE) could lead to IV-free regimens and at-home administration. 3. **Hypercon product progress and updates**: An analyst asked for an update on the progress of Hypercon products towards clinical testing, what remains to be done before Phase I, and what updates to anticipate regarding the products and development strategy. *Management Response*: Helen Torley confirmed that 2 Hypercon programs, involving established blockbuster mechanisms of action, are on track to enter Phase I clinical testing by the end of 2026. Remaining steps include completing clinical scale-up batches and filing IND packages. She noted that updates would be partner confidential but likely posted on clinicaltrials.gov, and the development pathway would be familiar, involving Phase I for dose identification and Phase III for non-inferiority. | Total revenue for the full year 2025 grew 38% to $1.4 billion. Royalty revenue for the full year 2025 increased 52% to $867.8 million. DARZALEX subcutaneous royalty revenue grew 29% year-over-year for the full year 2025. PHESGO royalty revenue grew 51% year-over-year for the full year 2025. VYVGART and VYVGART Hytrulo royalty revenue grew 444% year-over-year for the full year 2025. Total revenue for the fourth quarter of 2025 increased 52% to $451.8 million. Royalty revenue for the fourth quarter of 2025 increased 51% to $258 million. Product sales also contributed to the year-over-year total revenue growth for the full year 2025, though a specific percentage was not provided. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Halozyme expanded its portfolio from 2 to 4 subcutaneous drug delivery technologies with the acquisitions of Elektrofi's Hypercon and Surf Bio's hyperconcentration technologies, both with long-duration IP into the mid-2040s, significantly broadening collaboration opportunities across various targets, modalities, and therapeutic areas. DARZALEX FASPRO received approval in the U.S. for smoldering multiple myeloma, and Johnson & Johnson announced another approval for newly diagnosed multiple myeloma patients, marking the 12th indication overall. RYBREVANT subcutaneous with ENHANZE achieved regulatory approvals in the U.S., Japan, and China. Roche nominated a new ENHANZE target, and argenx expanded its ARGX-121 Phase I study with ENHANZE, indicating partners moving earlier-stage assets into subcutaneous development. Halozyme signed 3 new ENHANZE collaboration and licensing agreements, extending its reach beyond oncology into obesity and inflammatory bowel disease. OCREVUS ZUNOVO is expanding the addressable market by enabling use in community practices and overcoming intravenous infusion capacity constraints. VYVGART Hytrulo is exploring expanded and new indications for long-term growth. The company recognizes ENHANZE's potential to improve the clinical profile and convenience of antibody drug conjugates and nucleic acids. Hypercon is designed to meet the growing demand for lower volume auto-injector-ready at-home or in HCP office therapies, and by 2028, the combined commercial and development portfolio with ENHANZE, Hypercon, and Surf Bio is expected to nearly double from 19 to 36 products. | Halozyme expects to enter discussions with Johnson & Johnson to extend their ENHANZE agreement and API supply beyond 2032, indicating J&J's reliance on Halozyme's API and its strong reliability and safety track record. ENHANZE is recognized as the 'gold standard' for use with monoclonal antibodies, reflecting a strong competitive position. The company is involved in an IPR filed against Alteogen and a District Court litigation against Merck, alleging infringement of multiple Halozyme patents, highlighting efforts to defend its intellectual property against competitive challenges. | There is a significant industry push towards moving treatments to simple, short, small injections that can be administered in a doctor's office or at home, particularly for conditions like autoimmune diseases, neurology, and nephrology. This shift towards subcutaneous administration is expected to lead to a significant reduction in patients needing to visit infusion centers. The company also highlights the emerging and rapidly growing classes of antibody drug conjugates and nucleic acids as areas where drug delivery technologies like ENHANZE can improve clinical profiles and convenience. | Halozyme aims to be the 'one-stop shop' for the biopharma industry for subcutaneous drug delivery. DARZALEX sales are projected to exceed $18 billion in 2028, and PHESGO is expected to reach $3.6 billion in 2028. The combined IV and subcutaneous opportunity for OCREVUS, OPDIVO, RYBREVANT, and TECENTRIQ is estimated at approximately $30 billion in 2028. BMS targets 30% to 40% conversion for OPDIVO Qvantig by its loss of exclusivity in 2028. Halozyme anticipates royalty revenue durability and exceptional value creation well into the 2040s. In 2026, 6 new ENHANZE programs and 2 new Hypercon programs are projected to enter Phase I, expanding the development portfolio to 15 products, with accelerated royalty contributions from the pipeline expected to begin in 2029. The company expects 1 to 3 new ENHANZE agreements and 1 to 2 new Hypercon agreements in 2026. Hypercon's first approvals are projected in 2030-2031, with approximately $1 billion in Hypercon royalty revenue expected within 5 years of these launches in the mid-2030s. Surf Bio's clinical readiness is targeted for late 2027 or 2028. By 2028, the combined commercial and development portfolio is expected to nearly double to 36 products. Halozyme plans to continue strategic M&A to expand its drug delivery portfolio and acquire assets for near-term and long-term growth. For 2026, the company reiterates total revenue guidance of $1.71 billion to $1.81 billion, and royalty revenue guidance of $1.13 billion to $1.17 billion. Adjusted EBITDA is projected between $1.125 billion and $1.205 billion, with non-GAAP diluted EPS of $7.75 to $8.25. First-quarter royalty revenues are expected to decrease sequentially by 5% to 10% from Q4 2025 due to contractual rate resets, with sequential growth thereafter, and total revenue to decrease sequentially in Q1 2026 due to milestone weighting in the second half of the year. | Pharma/Therapeutics: | A broader theme emerging is the strong industry push towards patient-centric care, emphasizing the shift of drug administration to simpler, shorter, and smaller injections that can be done at home or in a doctor's office, giving patients more control over their treatment. This trend is leading to a significant reduction in the need for patients to visit infusion centers as more drugs become available in subcutaneous formulations. The increasing importance of advanced drug delivery technologies like ENHANZE, Hypercon, and Surf Bio in enabling this shift and enhancing the clinical profile of emerging drug classes is also a prominent theme. | 2025 was one of the most significant and value-creating years in Halozyme's history. Halozyme as the one-stop shop for the biopharma industry for subcutaneous drug delivery. DARZALEX is expected to continue this strong trajectory with sales projected to exceed $18 billion in 2028. We have multiple levers and drivers of revenue that will position Halozyme for royalty revenue durability and exceptional value creation well into the 2040s. Interest for ENHANZE has never been higher from pharma and biotech. We are projecting that... approximately $1 billion in Hypercon royalty revenue within 5 years of the first launches. By 2028, we expect our combined commercial and development portfolio... to nearly double from 19 products today to 36. We are pleased to reiterate our 2026 financial guidance. | Net income for the full year was $316.9 million, which includes $285 million of acquired IPR&D expense related to the Surf Bio acquisition. Both 2025 GAAP and non-GAAP diluted EPS included the unfavorable impact of approximately $2.30 per share from the Surf Bio acquired IPR&D expense. We expect first quarter royalty revenues to be less than the fourth quarter of 2025 by approximately 5% to 10% due to annual contractual rate resets. We project total revenue to decrease sequentially from the fourth quarter of 2025 to the first quarter of 2026 as no milestones are planned in the first quarter. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-02-17 | Halozyme reported strong 2025 results and robust 2026 guidance, driven by ENHANZE product growth and new technologies like Hypercon and ADC opportunities. Despite this positive outlook and strategic expansions, the market reacted negatively, with the stock significantly underperforming SPY by 11.80% post-earnings. This suggests investor disappointment, possibly due to high expectations, the IPR&D charge, or the projected Q1 2026 revenue cadence. | Other | Bearish | False | -11.80% (vs SPY: -12.76%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| HALO_76c37dda | In 2026 | 2026-01-01 | 2026-12-31 | Six new ENHANZE programs are projected to enter Phase I clinical studies. | This expands Halozyme's development portfolio, providing future royalty opportunities and demonstrating continued partner interest in the ENHANZE technology, which could positively impact long-term revenue and investor sentiment. | Ticker | 2026-02-17 | earnings_transcript |
| HALO_eb734522 | by the end of 2026 | 2026-10-01 | 2026-12-31 | Two Hypercon programs are expected to enter Phase I clinical testing. | This marks the clinical advancement of Halozyme's new Hypercon technology, validating its potential and laying the groundwork for future royalty streams, which could enhance long-term valuation. | Ticker | 2026-02-17 | earnings_transcript |
| HALO_033f0678 | In 2026, we plan to deliver at least 3 new licensing agreements, including between 1 and 3 new ENHANZE collaborations and between 1 and 2 new Hypercon collaborations. | 2026-01-01 | 2026-12-31 | Halozyme plans to sign at least 3 new licensing agreements in 2026, comprising 1-3 new ENHANZE collaborations and 1-2 new Hypercon collaborations. | New agreements expand Halozyme's partner base and technology adoption, providing upfront payments and future royalty opportunities, which could positively impact revenue and investor sentiment. | Ticker | 2026-02-17 | earnings_transcript |
| HALO_03d2d454 | both parties will appear before the District Court in June following the output of the PTAB to receive further information and instructions. | 2026-06-01 | 2026-06-30 | Halozyme and Merck are expected to appear before the District Court in June for further information and instructions regarding the patent infringement case. | The outcome of this litigation could significantly impact Halozyme's intellectual property rights and future royalty potential from KEYTRUDA SC, affecting valuation and investor sentiment. | Ticker | 2026-02-17 | earnings_transcript |
| HALO_e2398b02 | milestones expected to be weighted in the second half of the year | 2026-07-01 | 2026-12-31 | Halozyme expects milestone revenues to be weighted towards the second half of 2026. | The timing and value of these milestones will impact Halozyme's total revenue for 2026, with the realization of these payments being a key driver for meeting annual guidance. | Ticker | 2026-02-17 | earnings_transcript |
| HALO_33430303 | as the year progresses | 2026-03-03 | 2026-12-31 | Halozyme anticipates progress with its high-volume auto-injector, potentially including new partnerships or advancements in development. | Successful development and partnerships for the auto-injector could expand Halozyme's product offering and create new revenue streams, enhancing its position as a comprehensive drug delivery solution provider. | Ticker | 2026-02-17 | earnings_transcript |